Anteris Technologies Ltd

Equities

AVR

AU0000088841

Medical Equipment, Supplies & Distribution

Delayed Australian S.E. Other stock markets 01:44:54 2024-05-21 am EDT			5-day change	1st Jan Change
20 ^AUD	+2.30%		-2.83%	+4.02%

May. 15	Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure with DurAVR	MT
Apr. 18	Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	MT

Admedus Limited Announces Resignation of Catherine Costello as Chief Financial Officer

November 18, 2018 at 05:15 pm EST

Admedus Limited announced that Chief Financial Officer, Catherine Costello, will leave the company on November 16, 2018. The restructure of Admedus in Australia will see a change to the functions and responsibilities of the role.

Latest news about Anteris Technologies Ltd

Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure with DurAVR	May. 14	MT
Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	Apr. 17	MT
Anteris Technologies Raises AU$23 Million for DurAVR Study	Apr. 09	MT
Anteris Declares Upbeat Results from Human Trials of Heart Valve	Mar. 13	MT
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Anteris Technologies Completes Enrollment for Heart Valve Device Study	23-10-17	MT
Anteris Technologies Secures AU$1 Million Tax Rebate for 2022	23-10-12	MT
Anteris Technologies Ltd(ASX:AVR) dropped from S&P Global BMI Index	23-09-18	CI
Anteris Technologies Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case	23-08-14	CI
Montefiore Enrolls Patients for US Early Feasibility Study for Anteris Technologies' DurAVR THV	23-08-09	MT
Anteris Technologies Announces First Successful Implantation of Duravr? Thv in A Valve-In-Valve Procedure	23-07-31	CI
Anteris Technologies Implants DurAVR THV in Valve-in-Valve Procedure; Shares Jump 3%	23-07-30	MT
Anteris Technologies Validates Efficacy of Aortic Valve Device	23-06-09	MT
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4%	23-05-17	MT
Anteris Technologies, v2vmedtech to Develop Heart Valve Repair Device	23-04-19	MT
Anteris Technologies Ltd acquired 30% stake in v2vmedtech, inc. for $0.37 million.	23-04-18	CI
Australian Shares Rise on Mining, IT Boost Ahead of US Inflation Data	23-04-12	MT
Anteris Technologies Secures US Patent for Heart Valve Product; Shares Rise 3%	23-04-12	MT
US FDA Allows Manufacturing to Start at Anteris Technologies' Expanded Production Facility for DurAVR THV	23-03-26	MT
Anteris Technologies Ltd Announces FDA Allows Manufacturing to Begin At Expanded Facility	23-03-26	CI
Anteris Technologies Ltd(ASX:AVR) added to S&P/ASX All Ordinaries Index	23-03-20	CI
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Anteris Technologies Ltd Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Anteris Technologies Raises AU$35 Million for Heart Valve Development	23-02-09	MT

Chart Anteris Technologies Ltd

Duration

Period

More charts

Company Profile

Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Companyâs lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heartâs native commissures to achieve ideal valve positioning.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-28 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Anteris Technologies Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.55 AUD

Average target price

30 AUD

Spread / Average Target

+53.45%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ANTERIS TECHNOLOGIES LTD	+4.02%	251M
ABBOTT LABORATORIES	-6.23%	180B
MEDTRONIC PLC	+2.59%	112B
BECTON, DICKINSON AND COMPANY	-2.75%	68.53B
DEXCOM, INC.	+5.32%	51.97B
CENCORA, INC.	+7.61%	44.08B
HOYA CORPORATION	+5.33%	42.23B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.17%	32.43B
TERUMO CORPORATION	+16.49%	26.39B
WEST PHARMACEUTICAL SERVICES, INC.	-2.66%	24.97B

Other Medical Equipment, Supplies & Distribution